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This in vivo study was designed to investigate the potential of aluminium (Al), in the absence of added 
iron, to participate in either antioxidant or pro-oxidant events. Some markers of oxidative stress were 
determined in liver and brain of rats exposed to aluminium lactate, either alone or in the presence of 
dietary supplements of selenium (se) as selenite. Exposure to aluminium for 21 days resulted in a 
statistically significant (P<0.05) decrease in brain glutathione. However, a non-significant increase in 
hepatic glutathione was observed in animals supplemented with either Se or Al, but Al in combination 
with Se prevented this elevation. In the brain a statistically non-significant increase (P>0.05) was 
observed in the GSH content. Contrary to what is known, Al exposure resulted in statistically significant 
decrease (P<0.001) in lipid peroxidation as measured by production of malondialdehyde in both liver 
and brain. Aluminium exposure had no significant effect on the liver and brain superoxide dismutase 
activity. Results of the present study suggest that in rat aluminium exposure may have both pro-oxidant 
and antioxidant effect. Furthermore, Se supplementation may offer some protection against aluminium 
toxicity but this needs to be further elucidated.  
 
Key words: Aluminium, selenium, rat, brain, liver, antioxidant enzymes. 
 
 
INTRODUCTION 
 
Long-term haemo-dialysis using fluids containing 
aluminium has been associated with encephalopathy 
(Alfrey et al., 1976), oesteomalacia (Parkinson et al., 
1979) and anaemia (Elliott et al., 1978) due to aluminium 
toxicity. Dialysis dementia is characterised by speech 
disorders,    myoclonus,    coma    and    possibly     death  
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(McMillan et al., 1993). In experimental models of 
aluminium toxicity, encephalopathy, nerve cell 
degeneration, demyelination of the brain stem cells, and 
impaired motor co-ordination are observed (Ebina et al., 
1984). Cerebral accumulation of aluminium has also 
been reported in several other neuro-pathological 
disorders including Alzheimer’s disease (Good et al., 
1992; Lukiw, 1997; Perl and Brondy, 1980), Down’s 
syndrome (Crapper et al., 1973), amylotrophic lateral 
sclerosis (Gadjusek and Salazer, 1982; Perl et al.,  1982)  
   
 
 
 
 
and the dementia of Parkinson’s disease (Hirsch et al., 
1991). The role of aluminium in these disorders is less 
clear, however high concentrations of aluminium are 
found in certain regions of the brains of patients with 
Alzheimer’s disease (Kellett et al., 1986; Perl and Brody, 
1980; Crapper et al., 1976; 1980). There is also an 
epidemiological association between aluminium in 
drinking water and the incidence of Alzheimer’s disease 
(Martyn et al., 1989). Histological analysis have also 
revealed high concentration of aluminium in the nuclei of 
neurones associated with neurofibrillary tangle in 
Alzheimer’s disease, and senile plaques (Candy et al., 
1986). 
Despite the ample clinical and experimental data, the 
mechanisms of aluminium toxicity remain largely 
unknown. In vitro and in vivo experimental studies have 
implicated the formation of reactive oxygen species in the 
potential neurotoxic effect of aluminium, particularly in 
Alzheimer’s disease (Halliwell, 1992; Evans, 1993). 
Zaman (1994) showed that Al stimulates NADPH 
oxidation and takes part in the process of free radical 
formation. Experimental animal models and cell culture 
studies reveal that aluminium affects the expression of 
superoxide dismutase (SOD), catalase (CAT), glutathione 
peroxidase and glutathione (GSH) possibly leading to 
membrane fragility as a consequence (Julka and Gill, 
1996; Oteiza et al., 1993; Campbell et al., 1999). These 
data support the role of oxidative stress in aluminium 
induced cellular dysfunction and if this is indeed the case, 
antioxidants, such as selenium, may be protective. The 
aim of the present study was to investigate the effect of 
administering high doses of aluminium on indices of 
oxidative stress in the rat and their modulation by dietary 
selenium.  
 
 
MATERIALS AND METHODS 
 
Experimental animal model 
 
Twenty male Wistar albino rats weighing 170-180 g were divided 
into 4 experimental groups, each consisting of 5 rats: 
 
• First group was injected (i.p.) with an aqueous solution of 
aluminium lactate (Johnson Matthey GmbH, Zeppelinstraβe 7, 
Karlsruhe, germany), at a dose of 5 mg aluminium per kg body 
weight per day five times per week for 3 weeks. Animals 
received a standard chow diet (SDS) during this time.  
• The 2nd group was injected with similar volume of normal 
saline over the same period and received a standard chow diet 
ad libitum. 
• A 3rd group of rats was injected with aluminium as for (i) but 
received a chow supplemented with 1 mg/kg selenium as 
sodium selenite (Sigma Chemical Company Poole, Dorset, 
UK).  
• The 4th group received dietary selenium only without receiving 
i.p. aluminium.  
 
All animals were individually weighed and examined daily, with 
food  and  water   intakes   recorded.   They   were   all   housed   in  
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polypropylene cages to avoid extraneous trace element 
contamination. 
Animals were sacrificed by anesthetic overdose using sodium 
pentabarbitone (100 mg/kg). Blood was withdrawn via the dorsal 
vena cava into lithium heparin tubes and tissues (liver, kidney, 
spleen, brain and bone) removed, weighed and stored in 
aluminium-free plastic containers at -80oC until analysis. The brain 
was quickly excised, rinsed with cold 0.14 M NaCl and 
homogenized in 25% ice cold 50 mM Tris-HCl buffer pH 7.4  
(Benjamin et al., 1978). 
 
 
Trace element analysis 
 
Weighed tissue samples (0.1-0.5 g) were digested with 90% nitric 
acid and 70% perchloric acid for measurement of aluminium as 
previously described (Taylor and Walker, 1992) or nitric acid, 
perchloric acid and sulphuric acid in the case of selenium. 
Aluminium in the plasma or digested tissue samples was 
determined by electrothermal atomic absorption spectrometry 
(ETAAS) and selenium by hydride generation atomic absorption 
spectrometry (AAS).  
 
 
Measurement of reduced glutathione 
 
Liver and brain homogenates were diluted 10-fold with perchloric 
acid (70% v/v), and centrifuged for 10 min at 5,000 x g.  Fifty 
microlitres of sample was transferred to 1.5 ml of phosphate-EDTA 
buffer, followed by the addition of 50 µl o-phthaldialdehyde, and 
after vortexing was allowed to stand at room temperature in the 
dark for 30 min.  Thereafter the fluorescence intensity was 
measured using a fluoremeter with an excitation of wavelength of 
340 nm, and emission wavelength of 420 nm (Hissin and Hilf, 
1979).  
 
 
Measurement of superoxide dismutase activity 
 
Tissue samples (30-60 mg) were pulverized in a Braun 
Microdismembrator II (B Braun Biotech Inc.) in 200 µl of the 
homogenising buffer (50 mmol/L potassium phosphate, pH 7.4 
containing 0.3 mol/L KBr and 300 µl of protease inhibitor cocktail). 
Homogenates were sonicated for 20 min, centrifuged for 15 min at 
20,000 x g and the supernatant stored at -80oC until required. The 
superoxide dismutase activity was determined by a direct 
spectrophotometric method using Randox kits as previously 
described by Marklund (1976, 1985).  
 
 
Measurement of tissue lipid peroxidation  
 
One hundred and fifty microliter of the tissue supernatant or 50 µl of 
samples were diluted to 500 µl with doubled-deionized water. 250 µl 
of 1.34% thiobarbituric acid was added to all the tubes followed by 
addition of an equal volume of 40% trichloroacetic acid. The mixture 
was shaken and incubated for 30 min in a boiling water bath. Tubes 
were allowed to cool to room temperature and the absorbances 
read at 532 nm using zero concentration as blank (Gutteridge and 
Quilan, 1983; Hartman, 1983). 
 
 
Protein determination 
 
The total protein content of tissue homogenate was determined 
according to the method of Lowry et al. (1951).  
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                   Table 1. Aluminium and Selenium Concentration injected with these metals. 
 
Aluminium                                 Selenium  Group 
Plasma (µg/L) Liver (µg/g) Brain (µg/g) Plasma (µg/L) Liver (µg/g) Brain (µg/g) 
Control 3.28 ± 0.3 0.159 ± 0.0 0.02 ± 0.0 562 ± 49.1 7.00 ± 0.4 1.35 ± 0.0 
Al 218 ± 47.5***, *** 29.48 ± 3.4**, * 1.83 ± 0.3a+ b* 384 ± 51.3 *, * 6.50 ± 0.2 1.47 ± 0.0 
Se 3.00 ± 0.1 0.177 ± 0.0 0.15 ± 0.0 515 ± 26.7 8.40 ± 0.9 1.35 ± 0.1 
Al + Se 203 ± 36.1 **, ** 11.83 ± 2.54* 0.61 ± 0.2# 603 ± 52.8 # 9.00 ± 0.3# 1.49 ± 0.1 
 
Values are means ± SEM for (n=5). Comparison was assessed for signifficance using one way ANOVA and unpaired t-tests 
for normal distributed data. 
* P<0.05, ** P<0.001, and *** P<0.001 compared to control. 
* P<0.05, ** P<0.001, and *** P<0.001 compared to selenium treated group. 
# P<0.05, ## P<0.001, and ### P<0.001 compared to aluminium treated group. 
 
 
 
 
                          Table 2. Tissue Protein and Malondialdehyde content injected with Al and Se. 
 
Protein (mg/g tissue) Malondialdehyde content 
(nmoles MDA/mg protein) 
Group 
Liver  Brain  Liver  Brain 
Control 169.7  ± 5.6  42.8 ± 0.5 0.2 ± 0.019 3.7 ± 0.2 
Al 150.9 ± 5.3 * 51.9 ± 0.9*** 0.1 ± 0.019 ** 2.2 ± 0.1*** 
Se 167.3 ± 7.8  50.0 ± 0.8** 0.1 ± 0.012** 2.3 ± 0.2*** 
Al + Se 160.6 ± 10.4 49.5 ± 1.3*** 0.1 ± 0.024 * 2.0 ± 0.1*** 
 
Values are means ± SEM for (n=5). Comparison was assessed for signifficance using one way ANOVA and 
unpaired t-tests for normal distributed data. 
* P<0.05, ** P<0.001, and *** P<0.001 compared to control. 
* P<0.05, ** P<0.001, and *** P<0.001 compared to selenium treated group. 
# P<0.05, ## P<0.001, and ### P<0.001 compared to aluminium treated group. 
 
 
 
 
Statistical analysis 
 
Data were expressed as mean ± standard error of the mean (SEM) 
and results tested for statistical significance using unpaired 
Student’s t-test’s or one way analysis of variance (ANOVA).  
 
 
RESULTS 
 
Plasma aluminium concentrations were significantly 
higher (P < 0.01) in both of the groups treated with 
aluminium (Table 1). Plasma selenium concentrations 
were significantly lower in the rats receiving aluminium 
alone compared to other groups. 
The aluminium content of brain and liver was also 
significantly increased in both aluminium-treated groups 
(P < 0.01). Treatment with dietary selenium was 
associated with a significant reduction (P < 0.05) in brain 
and liver aluminium content (Table 1). 
Plasma selenium concentrations were not significantly 
different in rats receiving dietary selenium supplements 
alone (P > 0.05).  Aluminium treatment was associated 
with a lower selenium concentration compared to controls 
(P < 0.05) in plasma and liver. Liver selenium 
concentration was significantly higher in animals 
receiving selenium and aluminium compared to those 
receiving aluminium alone (P < 0.05) (Table 1). 
The protein content of liver tissue was decreased in the 
aluminium-treated group but no significant differences 
were seen between the other groups. In the brain 
however, there was a significant increase in all of the 
treated groups in comparison to the control (P < 0.01) 
(Table 2). 
The malondialdehyde content (a measure of lipid 
peroxidation) was significantly lower in liver (P < 0.05) 
(Table 3) and brain (P < 0.01) of rats receiving aluminium 
and/or selenium. The GSH content in the  brain  revealed  
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                         Table 3. Superoxide dismutase activity and Reduced glutathione injected with Al and Se. 
 
Superoxide dismutase activity 
(units/mg protein) 
Reduced glutathione  
  (nmoles GSH/mg protein) 
 
Group 
Liver  Brain Liver Brain 
Control 9.2 ± 0.6 2.6 ± 0.1 1.1 ± 0.1 3.8 ± 0.3 
Al 9.6 ± 0.9 2.3 ± 0.2 1.3 ± 0.1 4.0 ± 0.2  
Se 7.4 ± 0.7 2.1 ± 0.1 1.3 ± 0.1 4.8 ± 0.2  
Al + Se 10.1 ± 1.2 2.3 ± 0.1 1.2 ± 0.1 4.3 ± 0.2  
 
Values are means ± SEM for (n=5). Comparison was assessed for signifficance using one way ANOVA and 
unpaired t-tests for normal distributed data. 
* P<0.05, ** P<0.001, and *** P<0.001 compared to control. 
* P<0.05, ** P<0.001, and *** P<0.001 compared to selenium treated group. 
# P<0.05, ## P<0.001, and ### P<0.001 compared to aluminium treated group. 
 
 
 
a statistically non-significant increase in all of the groups. 
Hepatic and brain SOD were not significantly affected by 
treatment with aluminium or selenium (Table 3). 
 
 
DISCUSSION 
 
A search for the understanding of the cellular and 
molecular basis of aluminium toxicity has stimulated very 
many experimental studies. A possible role of oxygen 
radicals in neurodegenerative diseases has been a topic 
of burgeoning research investigation. In the present in 
vivo studies an attempt has been made to delineate the 
potential of aluminium to participate independently 
without iron as an antioxidant and pro-oxidant.  
Intraperitoneal administration of aluminium resulted in a 
significant increase in plasma and tissue aluminium 
concentration. There was no signs or symptom of toxicity 
in the animals, apart from reduction in food and water 
intake. This supports the observation of Van der Voet et 
al. (1992) who reported accumulation of aluminium in rat 
liver after intraperitoneal injection of AlCl3. However, the 
relationship between tissue aluminium levels and Al 
toxicity is highly complicated because elevated tissue 
aluminium levels does not necessarily produced 
detrimental effects. However, during autopsy of the rats 
in this study, the only gross pathological changes 
observed were in the aluminium treated groups. There 
were smooth, solid and white inclusions, which were 
about 3 mm x 2 mm in size, either floating freely in the 
abdominal cavity or attached to an abdominal organ such 
as liver and spleen. Aluminium is, neverthyeless, toxic to 
man and other vertebrates (Alfrey et al., 1980).  
Generally, selenium treatment alone showed no 
significant difference from the control. This may be due to 
high level of selenium found in normal rat diet (0.5 
mg/kg). This amount might be incorporated into SH-
proteins. Over 80% of aluminium in serum/plasma is 
bound to transferrin, a major serum binding protein. 
Some of the observed effects of aluminium were 
completely abolished by Se-supplementation. These 
suggest that Se have an effect on aluminium distribution 
within the tissues. Since the effects were not observed in 
the plasma, Se supplementation may not have any effect 
on aluminium excretion.  
We observed no significant changes in SOD activity 
after Al-exposure. But Rudenko (1999) reported that the 
Se group showed a different response. However, the lack 
of significant changes in SOD activity after aluminium 
exposure is supported by the work of Chainy et al, 
(1996). This indicates that the dietary Se 
supplementation has less influence on the brain. It is 
really difficult to determine precisely the exact aluminium-
Selenium interaction in this case. However, one can 
suggest that in the presence of aluminium, Selenium is 
being depleted from the tissues due to aluminium burden. 
Since Selenium can cause an increase in protein via 
increasing the levels of selenoprotein, particularly the 
thiol containing proteins, notably the glutathione and its 
enzyme related forms, which are most sensitive to 
alterations in selenium status. 
The potential role of aluminium involvement in oxidation 
activities remains controversial to-date. Evidence for 
(Oteiza et al., 1993; Exley, 1999; Evans, 1993) and 
against (Xie et al., 1995; Oteiza et al., 1993) its potential 
involvement has both been reported. The present work 
contributes to the existing debate on aluminium as 
antioxidant at low concentration and pro-oxidant at high 
concentration. Similarly, suggesting that aluminium might 
facilitate membrane peroxidation by increasing their 
susceptibility to free radical induced damage (Van 
Rensburg et al., 1997; Ohyashiki et al., 1998). 
The data are difficult to interpret, as the result in the liver 
is completely the reversed of what was observed in the 
brain. Nevertheless, the liver result is in conformity to the 
report  of  Bondy  et  al.  (1998).  The  decrease  in   MDA  
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production in both liver and brain are contrary to most 
published reports (Yoshino et al., 1999; Chainy et al., 
1996; Meglio and Oteiza, 1999). Although under certain 
conditions free aluminium ion has been reported to inhibit 
malondialdehyde production (Oteiza et al., 1993). Most 
workers incorporate iron in their studies to cause 
aluminium to exert its deleterious pro-oxidant effects. 
There is no doubt that aluminum has the potential to 
cause both oxidative and antioxidative effects which 
explain why some workers reported a more profound 
effect of aluminium oxidative effects in the presence of 
iron rather than aluminium alone. Hence if aluminium 
induces reactive oxygen species this would eventually 
lead to a cascade chain of reaction leading to toxicity. 
Therefore, an antioxidant could reduce aluminium-
induced toxicity. 
The dual or biphasic effect of aluminium exposure 
observed in these experiments is probably due to direct 
interaction of aluminium with cellular components, rather 
than to reaction with oxidative-reactive species. Biphasic 
effect of aluminium has been reported in diverse cell 
system including phosphorylation of neurofilament sub-
units (Letterier et al., 1992). The effect may be due to the 
formation of aluminium complexes with indirect effect on 
free radical scavenging enzymes and glutathione. 
From the presented in vivo studies, it can be concluded 
that aluminium exposure may have some potential to 
promote pro-oxidant event and that Se-supplementation 
may likely help in preventing these deleterious pro-
oxidant effect. However, these need to be further 
substantiated. 
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